At CTO East Coast, experts reflected on designing oncology clinical trials for success and how to account for a shifting geopolitical landscape in the US.

The trial's principal investigator Pasi Janne said the results support osimertinib "as standard of care" for EGFR-mutated cancer patients. Janne also noted that AstraZeneca's drug "did not impose any ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved survival rates for patients.

Positive high-level results have been presented from the final overall survival (OS) analysis of the FLAURA2 Phase III trial.

A once-daily tablet that can help people suffering from hay fever caused by birch tree pollen, Alk-Abelló's Itulazax, has ...

AstraZeneca has bolstered the standing of Tagrisso as a first-line treatment for locally advanced or metastatic EGFR-mutated ...

On 21 July 2025, the Court of Appeal delivered a significant ruling in AstraZeneca AB & Anor v Generics (UK) Limited & Ors, ...

AstraZeneca (AZ) has shared positive overall survival (OS) results from a late-stage study of its epidermal growth factor ...

Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based ...

As biopharma innovation becomes increasingly data-driven and autonomous, the integration of Chinese AI- renowned for rapid ...

AstraZeneca shares have dropped substantially from their record-breaking heyday in September, but is this the ideal time for me to buy more of them? The post Is it worth me buying more AstraZeneca ...